{"id":"https://openalex.org/W3110990649","doi":"https://doi.org/10.1016/j.jval.2020.08.1381","title":"PND56 Cost-Effectiveness of Erenumab for the Prevention of Migraine in Portugal","display_name":"PND56 Cost-Effectiveness of Erenumab for the Prevention of Migraine in Portugal","publication_year":2020,"publication_date":"2020-12-01","ids":{"openalex":"https://openalex.org/W3110990649","doi":"https://doi.org/10.1016/j.jval.2020.08.1381","mag":"3110990649"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2020.08.1381","doi":"https://doi.org/10.1016/j.jval.2020.08.1381","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2020.08.1381","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","cwts-core","doyens","jufo-2","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/j.jval.2020.08.1381","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080945210","display_name":"C. Silva","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Silva","raw_affiliation_strings":["Novartis Farma, Set\u00fabal, 11, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Farma, Set\u00fabal, 11, Portugal","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. Monge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4403386565","display_name":"Novartis Farma SA (Portugal)","ror":"https://ror.org/03fjwdh27","country_code":"PT","type":"company","lineage":["https://openalex.org/I4403386565"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"S. Monge","raw_affiliation_strings":["Novartis Farma, Porto Salvo, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Farma, Porto Salvo, Portugal","institution_ids":["https://openalex.org/I4403386565"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086737577","display_name":"Philip Cooney","orcid":"https://orcid.org/0000-0001-9649-0195","observed_orcids":["https://orcid.org/0000-0001-9649-0195"]},"institutions":[{"id":"https://openalex.org/I4210154767","display_name":"Novartis (Ireland)","ror":"https://ror.org/04sgnw557","country_code":"IE","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210154767"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"P. Cooney","raw_affiliation_strings":["Novartis Ireland Limited, Dublin, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Ireland Limited, Dublin, Ireland","institution_ids":["https://openalex.org/I4210154767"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004135550","display_name":"R Mahon","orcid":"https://orcid.org/0009-0007-3500-5951","observed_orcids":["https://orcid.org/0009-0007-3500-5951"]},"institutions":[{"id":"https://openalex.org/I4210154767","display_name":"Novartis (Ireland)","ror":"https://ror.org/04sgnw557","country_code":"IE","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210154767"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"R. Mahon","raw_affiliation_strings":["Novartis Ireland Limited, Dublin, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Ireland Limited, Dublin, Ireland","institution_ids":["https://openalex.org/I4210154767"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042827419","display_name":"P.A. Laires","orcid":"https://orcid.org/0000-0002-1930-7913","observed_orcids":["https://orcid.org/0000-0002-1930-7913"]},"institutions":[{"id":"https://openalex.org/I4403386565","display_name":"Novartis Farma SA (Portugal)","ror":"https://ror.org/03fjwdh27","country_code":"PT","type":"company","lineage":["https://openalex.org/I4403386565"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"P.A. Laires","raw_affiliation_strings":["Novartis Farma, Porto Salvo, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Farma, Porto Salvo, Portugal","institution_ids":["https://openalex.org/I4403386565"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2850,"currency":"USD","value_usd":2850},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":null,"first_page":"S633","last_page":"S633"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.975600004196167,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.975600004196167,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.022600000724196434,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10841","display_name":"Economic and Environmental Valuation","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erenumab","display_name":"erenumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/migraine-prevention","display_name":"migraine prophylaxis","score":0.9789999723434448},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.953000009059906},{"id":"https://openalex.org/keywords/treatment-failure","display_name":"treatment failure","score":0.4620000123977661},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.5410000085830688}],"concepts":[{"id":"https://openalex.org/C2778541695","wikidata":"https://www.wikidata.org/wiki/Q133823","display_name":"Migraine","level":2,"score":0.8285136222839355},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7717198729515076},{"id":"https://openalex.org/C6964187","wikidata":"https://www.wikidata.org/wiki/Q659256","display_name":"Indirect costs","level":2,"score":0.5724713802337646},{"id":"https://openalex.org/C127454912","wikidata":"https://www.wikidata.org/wiki/Q942582","display_name":"Cost\u2013benefit analysis","level":2,"score":0.5141103863716125},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5140117406845093},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.49027279019355774},{"id":"https://openalex.org/C2780564907","wikidata":"https://www.wikidata.org/wiki/Q6844299","display_name":"Migraine treatment","level":3,"score":0.4682142734527588},{"id":"https://openalex.org/C27400517","wikidata":"https://www.wikidata.org/wiki/Q332278","display_name":"Absenteeism","level":2,"score":0.4646785855293274},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.4357392489910126},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.421189546585083},{"id":"https://openalex.org/C28761237","wikidata":"https://www.wikidata.org/wiki/Q7805321","display_name":"Time horizon","level":2,"score":0.4114912152290344},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.24919328093528748},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.1978072226047516},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.16904869675636292},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.1166844367980957},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.11185693740844727},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.09766519069671631},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.0878855288028717},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.07642108201980591},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0},{"id":"https://openalex.org/C121955636","wikidata":"https://www.wikidata.org/wiki/Q4116214","display_name":"Accounting","level":1,"score":0.0},{"id":"https://openalex.org/C18903297","wikidata":"https://www.wikidata.org/wiki/Q7150","display_name":"Ecology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C77805123","wikidata":"https://www.wikidata.org/wiki/Q161272","display_name":"Social psychology","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2020.08.1381","doi":"https://doi.org/10.1016/j.jval.2020.08.1381","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2020.08.1381","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","cwts-core","doyens","jufo-2","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2020.08.1381","doi":"https://doi.org/10.1016/j.jval.2020.08.1381","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2020.08.1381","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","cwts-core","doyens","jufo-2","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2134662772","https://openalex.org/W4242416360","https://openalex.org/W2993715754","https://openalex.org/W3211115967","https://openalex.org/W2222151703","https://openalex.org/W2289841487","https://openalex.org/W4383891193","https://openalex.org/W1121141779","https://openalex.org/W180292241","https://openalex.org/W1999193930"],"abstract_inverted_index":null,"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}